MedTrace Logo

Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition

NCT01390610 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2015-11-26

No results posted yet for this study

Summary

The purpose of this study is to use data from the Continuous Glucose Monitoring (CGM) device and your Self-Monitored Blood Glucose (SMBG) levels to determine the best times to test blood glucose levels using SMBG.

Conditions

  • Diabetes Mellitus, Type 2
  • Diabetic Blood Glucose Monitoring

Sponsors & Collaborators

  • Abbott Diabetes Care

    collaborator INDUSTRY

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Roger S Mazze, PhD · International Diabetes Center at Park Nicollet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01390610 on ClinicalTrials.gov